Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis

Previous studies indicate that prostate cancer antigen 3 (PCA3) is highly expressed in prostatic tumors. However, its clinical value has not been characterized. The aim of this study was to investigate the clinical value of the urine PCA3 test in the diagnosis of prostate cancer by pooling the publi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports Jg. 6; H. 1; S. 25776
Hauptverfasser: Cui, Yong, Cao, Wenzhou, Li, Quan, Shen, Hua, Liu, Chao, Deng, Junpeng, Xu, Jiangfeng, Shao, Qiang
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 10.05.2016
Nature Publishing Group
Schlagworte:
38
38/77
631/61/54
639/301/1019
Antigens
Antigens, Neoplasm - metabolism
Antigens, Neoplasm - urine
Clinical trials
Humanities and Social Sciences
Humans
Male
Meta-analysis
multidisciplinary
Odds Ratio
Prostate cancer
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - urine
ROC Curve
Science
Science (multidisciplinary)
Sensitivity and Specificity
Tumors
Urine
ISSN:2045-2322, 2045-2322
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Previous studies indicate that prostate cancer antigen 3 (PCA3) is highly expressed in prostatic tumors. However, its clinical value has not been characterized. The aim of this study was to investigate the clinical value of the urine PCA3 test in the diagnosis of prostate cancer by pooling the published data. Clinical trials utilizing the urine PCA3 test for diagnosing prostate cancer were retrieved from PubMed and Embase. A total of 46 clinical trials including 12,295 subjects were included in this meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (−LR), diagnostic odds ratio (DOR) and area under the curve (AUC) were 0.65 (95% confidence interval [CI]: 0.63–0.66), 0.73 (95% CI: 0.72–0.74), 2.23 (95% CI: 1.91–2.62), 0.48 (95% CI: 0.44–0.52), 5.31 (95% CI: 4.19–6.73) and 0.75 (95% CI: 0.74–0.77), respectively. In conclusion, the urine PCA3 test has acceptable sensitivity and specificity for the diagnosis of prostate cancer and can be used as a non-invasive method for that purpose.
Bibliographie:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Feature-2
content type line 23
ObjectType-Review-1
ObjectType-Article-3
ObjectType-Undefined-4
These authors contributed equally to this work.
ISSN:2045-2322
2045-2322
DOI:10.1038/srep25776